Domestic pharmaceutical company Geropharm received registration certificate for an ultra-short-acting insulin analogue. This is Aspart RinFast insulin, according to the website of the Ministry of Industry and Trade.
Patients will now be able to receive it in cartridges and pre-filled multi-dose disposable syringe pens.
RinFast is a biosimilar of the original NovoRapid drug. Prior to its registration, the only manufacturer of aspart insulin in the Russian Federation was the Danish company Novo Nordisk. Geropharm will produce the drug according to the full-cycle principle, starting from the substance to the finished drug.
Obtaining registration was another step in ensuring the country's independence from supplies of imported insulin substances.
According to Sergey Tsyb, the First Deputy Head of the Ministry, now the manufacturers have enough competence to develop the production of pharmaceuticals in the country that are independent of imports. He pointed to the need to further increase the list of drugs produced in Russia on a full cycle, as it has a positive impact on strengthening export opportunities and development of the domestic market.
Today the total volume of Russian market of insulin aspart is 3.4 bln roubles.
Made in Russia // Made in Russia
Author: Ksenia Gustova